Home/Pipeline/GF-CART02

GF-CART02

Multiple myeloma

PreclinicalActive

Key Facts

Indication

Multiple myeloma

Phase

Preclinical

Status

Active

Company

GenomeFrontier Therapeutics

About GenomeFrontier Therapeutics

Taiwan biotech leveraging virus‑free gene‑editing platforms to create CAR‑T/TCR‑T cell therapies for cancer.

View full company profile

Therapeutic Areas

Other Multiple myeloma Drugs

Drug	Company	Phase	Status
PRG1801 (Anti-BCMA CAR-T)	Pregene Biopharma	Phase 1	Active
CAR-NK Therapy	Pregene Biopharma	Phase 1	Active (recruiting)
Tasquinimod	Active Biotech	Preclinical	Active (Academic Partnership)
BCMA CAR-T	Simnova Biotherapeutics	Phase 1	Active
BCMA panCAR (via Orna partnership)	Simnova Biotherapeutics	Preclinical	Active
Measovir®-based candidate	Oncovita	Pre-clinical	Preclinical activity demonstrated
Kyprolis® (carfilzomib)	Cleo Life Sciences	Approved	Supported late-stage development & NDA
inobrodib (CCS1477)	CellCentric	Phase 1/2	Active
ISB 2001	Ichnos Glenmark Innovation	Phase 1b	Active
In Vivo Cell Therapy	GigaMune	Pre-clinical	Active
Hemady	Dexcel Pharma USA	Approved	Commercial
AV-353	AVEO Oncology	Pre-clinical	Active